Insight

Razan Mohty: Outcomes of patients with IDH1 or 2 mutated AML after alloHCT

Photo from Razan Mohty/X

Aug 17, 2024, 07:45

Razan Mohty: Outcomes of patients with IDH1 or 2 mutated AML after alloHCT

Razan Mohty, Assistant Professor at UAB Medicine, shared a post on X about a recent paper published in BMT journal.

“Isocitrate dehydrogenase (IDH) 1 and 2 mutations predict better outcome in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: a study of the ALWP of the EBMT”

Authors: Razan Mohty et al.

“Check our newly published article on outcomes of patients with IDH1 or 2 mutated AML after alloHCT, a study of the ALWP of The EBMT in BMT journal.

Thank you Abdul-Hamid Bazarbachi, Mohamad Mohty, Myriam Labopin, and all co-authors.”

Source: Razan Mohty/X

More posts by Razan Mohty in OncoDaily.

Abdul-Hamid Bazarbachi Acute Myeloid Leukemia alloHCT ALWP AML BMT journal cancer Mohamad Mohty Myriam Labopin OncoDaily Oncology Razan Mohty The EBMT UAB Medicine

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Giuliana Rancic and Breast Cancer: How She Went Against, How She Survived, and More

Vincent Rajkumar: Paradigm changing AQUILA randomized trial in high risk smoldering myeloma

"The Doctor Who Always Has Candies in His Pocket": A Conversation with Professor Guangchao Zhang, Pioneer of Pediatric Surgical Oncology in China

Special Coverage